leishmaniasis/tyrosine

Linkki tallennetaan leikepöydälle

Valitse lajittelutyyppi

Sivu 1 alkaen 67 tuloksia

Pancytopenia during tyrosine kinase inhibitor treatment - coexistence of chronic myeloid leukemia and visceral leishmaniasis: a case report.

Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita

Kirjaudu sisään Rekisteröidy

BACKGROUND Visceral leishmaniasis is a zoonosis characterized by chronic evolution of symptoms; it usually appears 2 to 4 months after the initial infection, with multiple cutaneous lesions and systemic involvement, which if left untreated results in death in 90 % of cases. METHODS We present a case

Inhibition of receptor tyrosine kinases restores immunocompetence and improves immune-dependent chemotherapy against experimental leishmaniasis in mice.

Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita

Kirjaudu sisään Rekisteröidy

Receptor tyrosine kinases are involved in multiple cellular processes, and drugs that inhibit their action are used in the clinic to treat several types of cancer. However, the value of receptor tyrosine kinase inhibitors (RTKIs) for treating infectious disease has yet to be explored. Here, we have

Protection against progressive leishmaniasis by IFN-beta.

Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita

Kirjaudu sisään Rekisteröidy

Type I IFNs (IFN-alphabeta) exert potent antiviral and immunoregulatory activities during viral infections, but their role in bacterial or protozoan infections is poorly understood. In this study, we demonstrate that the application of low, but not of high doses of IFN-beta protects 60 or 100% of

Flavones reversibly inhibit Leishmania donovani tyrosine aminotransferase by binding to the catalytic pocket: An integrated in silico-in vitro approach

Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita

Kirjaudu sisään Rekisteröidy

The current drugs for treating Leishmaniasis are toxic, non-economical and with the emergence of drug resistance makes the need for novel therapeutics urgent and necessary. In the current study, we report the identification of compounds TI 1-5 against tyrosine aminotransferase of L. donovani from a

Structure of tyrosine aminotransferase from Leishmania infantum.

Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita

Kirjaudu sisään Rekisteröidy

The trypanosomatid parasite Leishmania infantum is the causative agent of visceral leishmaniasis (VL), which is usually fatal unless treated. VL has an incidence of 0.5 million cases every year and is an important opportunistic co-infection in HIV/AIDS. Tyrosine aminotransferase (TAT) has an

EVALUATION OF AROMATIC 6-SUBSTITUTED THIENOPYRIMIDINES AS SCAFFOLDS AGAINST PARASITES THAT CAUSE TRYPANOSOMIASIS, LEISHMANIASIS, AND MALARIA.

Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita

Kirjaudu sisään Rekisteröidy

Target repurposing is a proven method for finding new lead compounds that target Trypanosoma brucei, the causative agent of human African trypanosomiasis. Due to the recent discovery of a lapatinib-derived analog 2 with excellent potency against T. brucei (EC50 = 42 nM) and selectivity over human

TGF-β-regulated tyrosine phosphatases induce lymphocyte apoptosis in Leishmania donovani-infected hamsters.

Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita

Kirjaudu sisään Rekisteröidy

Visceral leishmaniasis, which is caused by Leishmania donovani, is one of the major health problems of the Indian subcontinent. Infected hosts have been reported to have impaired lymphoproliferation. However, the fate of anergic cells is still elusive. In the present investigation, L.

Anion exchange through band 3 protein in canine leishmaniasis at different stages of disease.

Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita

Kirjaudu sisään Rekisteröidy

Band 3 protein efficiency in mediating Cl-/HCO3- exchange through erythrocytes membrane is reduced by oxidative stress. The aim of the present study was to verify whether and how anion transport through band 3 protein may be useful in monitoring canine leishmaniasis (Leishmania infantum)

Role of protein tyrosine phosphatases in the regulation of interferon-{gamma}-induced macrophage nitric oxide generation: implication of ERK pathway and AP-1 activation.

Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita

Kirjaudu sisään Rekisteröidy

NO is a potent molecule involved in the cytotoxic events mediated by macrophages (MØ) against microorganisms. We reported previously that inhibition of MØ protein tyrosine phosphatases (PTPs) mediates a protective effect against Leishmania infection, which was NO-dependent. Herein, we show that the

Regulation of the Leishmania-induced innate inflammatory response by the protein tyrosine phosphatase SHP-1.

Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita

Kirjaudu sisään Rekisteröidy

Modulation of the phagocyte protein tyrosine phosphatase (PTP) SHP-1 by the parasite Leishmania favors its survival and propagation within its mammalian host. In vivo, the absence of SHP-1 leads to virtually absent footpad swelling, accompanied by enhanced inducible nitric oxide synthase expression.

NRAMP-1 expression modulates protein-tyrosine phosphatase activity in macrophages: impact on host cell signaling and functions.

Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita

Kirjaudu sisään Rekisteröidy

NRAMP-1 (natural resistance-associated macrophage protein-1) has been associated with innate resistance to unrelated intracellular pathogen infections, up-regulation of proinflammatory phagocyte functions, and susceptibility to autoimmune diseases. It is still unclear how the divalent cation

Identification and characterization of a protein-tyrosine phosphatase in Leishmania: Involvement in virulence.

Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita

Kirjaudu sisään Rekisteröidy

Leishmania parasites are eukaryotic protozoans responsible for a variety of human diseases known as leishmaniasis, which ranges from skin lesions to fatal visceral infections. Leishmania is transmitted by the bite of an infected sandfly where it exists as promastigotes and, upon entry into a

Study of therapeutic effect of different concentrations of imatinib on Balb/c model of cutaneous leishmaniasis

Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita

Kirjaudu sisään Rekisteröidy

Leishmaniasis, as a tropical and subtropical disease, is endemic in more than 90 countries around the world. Today, cutaneous leishmaniasis (CL) that affects more than 1.5 million people per year lacks a definitive treatment approach. Imatinib is an anticancer drug that inhibits the abnormal

Tyrosine aminotransferase from Leishmania infantum: A new drug target candidate.

Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita

Kirjaudu sisään Rekisteröidy

Leishmania infantum is the etiological agent of zoonotic visceral leishmaniasis in the Mediterranean basin. The disease is fatal without treatment, which has been based on antimonial pentavalents for more than 60 years. Due to resistances, relapses and toxicity to current treatment, the development

Heterologous expression of a mammalian protein tyrosine phosphatase gene in Leishmania: effect on differentiation.

Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita

Kirjaudu sisään Rekisteröidy

Leishmania is a protozoan pathogen which is transmitted to humans through the bite of an infected sandfly. This infection results in a spectrum of diseases throughout the developing world, collectively known as leishmaniasis. During its life cycle, Leishmania differentiates from the promastigote

Edellinen
1
2
3
4
5
Seuraava

Liity facebook-sivullemme

Herbal & Natural Medicine

Täydellisin lääketieteellinen tietokanta tieteen tukemana

Toimii 55 kielellä
Yrttilääkkeet tieteen tukemana
Yrttien tunnistaminen kuvan perusteella
Interaktiivinen GPS-kartta - merkitse yrtit sijaintiin (tulossa pian)
Lue hakuusi liittyviä tieteellisiä julkaisuja
Hae lääkekasveja niiden vaikutusten perusteella
Järjestä kiinnostuksesi ja pysy ajan tasalla uutisista, kliinisistä tutkimuksista ja patenteista

Kirjoita oire tai sairaus ja lue yrtteistä, jotka saattavat auttaa, kirjoita yrtti ja näe taudit ja oireet, joita vastaan sitä käytetään.
* Kaikki tiedot perustuvat julkaistuun tieteelliseen tutkimukseen